Scott Galovan - Avanos Medical Senior Development
| AVNS Stock | USD 14.77 0.05 0.34% |
Executive
Scott Galovan is Senior Development of Avanos Medical
| Phone | 844 428 2667 |
| Web | https://avanos.com |
Avanos Medical Management Efficiency
The company has return on total asset (ROA) of 0.0197 % which means that it generated a profit of $0.0197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3742) %, meaning that it created substantial loss on money invested by shareholders. Avanos Medical's management efficiency ratios could be used to measure how well Avanos Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Roberto Donadello | Orthofix Medical | N/A | |
| Hollie Foust | CONMED | N/A | |
| Ross Mansbach | Establishment Labs Holdings | 57 | |
| Harold Tamayo | Axogen Inc | N/A | |
| Jonathan Friedman | Paragon 28 | 53 | |
| Julie Dewey | Orthofix Medical | 64 | |
| Lisa Funiciello | Anika Therapeutics | N/A | |
| Neeta Toprani | Establishment Labs Holdings | N/A | |
| John Ferrell | CONMED | 56 | |
| Scot JD | Treace Medical Concepts | 49 | |
| Todd Puckett | Axogen Inc | N/A | |
| Gordon Weber | SurModics | 61 | |
| Angeline McCabe | Nevro Corp | N/A | |
| Kashif JD | Nevro Corp | 50 | |
| Robert Thomson | Artivion | 55 | |
| Isabelle Billet | Axogen Inc | 62 | |
| Doris Quackenbush | Axogen Inc | N/A | |
| David Caraway | Nevro Corp | 63 | |
| Julie Dewey | Treace Medical Concepts | 63 | |
| Terry Lubben | Treace Medical Concepts | 59 | |
| Andrew Senn | Integer Holdings Corp | 43 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | 0.0197 |
Avanos Medical Leadership Team
Elected by the shareholders, the Avanos Medical's board of directors comprises two types of representatives: Avanos Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avanos. The board's role is to monitor Avanos Medical's management team and ensure that shareholders' interests are well served. Avanos Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avanos Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Cato, Vice Resources | ||
| S Mansbach, Senior Vice President Interim General Counsel, Corporate Secretary | ||
| Chip Zimliki, Senior Affairs | ||
| William Haydon, Senior Vice President and General Manager, Pain Management | ||
| Moji James, Senior Vice President General Counsel | ||
| Patrick OLeary, Independent Director | ||
| Sigfrido Delgado, Senior Operations | ||
| Jonathan Turner, VP Officer | ||
| Julie Shimer, Independent Director | ||
| Michelle Scharfenberg, Senior Vice President Chief Ethics and Compliance Officer | ||
| Gary Blackford, Independent Non-Executive Chairman of the Board | ||
| William Hawkins, Independent Director | ||
| David Ball, Senior Vice President - Global Supply Chain and Procurement | ||
| Mojirade James, Senior Vice President General Counsel, Corporate Secretary | ||
| Heidi Kunz, Independent Director | ||
| Lee Burnes, Clinical RD | ||
| Michael Greiner, Chief Financial Officer, Senior Vice President | ||
| Warren Machan, Interim Officer | ||
| Scott Galovan, Senior Development | ||
| Michael CPA, Senior CEO | ||
| Katrine Kubis, Vice Relations | ||
| Sudhakar Varshney, Senior Procurement | ||
| John Byrnes, Independent Director | ||
| Maria Sainz, Independent Director | ||
| Siobhan Smyth, VP Officer | ||
| Vinny Sastri, Senior Quality | ||
| David Crawford, VP Treasurer | ||
| Arjun Sarker, Senior Vice President - International | ||
| John Hurley, Principal Controller | ||
| Kerr Holbrook, Senior Vice President General Manager - Chronic Care | ||
| Joseph Woody, Chief Executive Officer, Director |
Avanos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avanos Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | 0.0197 | ||||
| Profit Margin | (0.57) % | ||||
| Operating Margin | 0.05 % | ||||
| Current Valuation | 735.53 M | ||||
| Shares Outstanding | 46 M | ||||
| Shares Owned By Insiders | 3.22 % | ||||
| Shares Owned By Institutions | 95.94 % | ||||
| Number Of Shares Shorted | 888.74 K | ||||
| Price To Earning | 51.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Avanos Stock Analysis
When running Avanos Medical's price analysis, check to measure Avanos Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avanos Medical is operating at the current time. Most of Avanos Medical's value examination focuses on studying past and present price action to predict the probability of Avanos Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avanos Medical's price. Additionally, you may evaluate how the addition of Avanos Medical to your portfolios can decrease your overall portfolio volatility.